

1 **Original article**

2

3 **Bacterial pulmonary superinfections are associated with unfavourable outcomes in**
4 **critically ill COVID-19 patients**

5

6 Philipp K. Buehler^{1*}, Annelies S. Zinkernagel^{2*}, Daniel A. Hofmaenner^{1*}, Pedro David Wendel
7 García¹ Claudio T. Acevedo², Alejandro Gómez-Mejía²; Srikanth Mairpady Shambat², Federica
8 Andreoni², Martina A. Maibach¹, Jan Bartussek^{1,4}, Matthias P. Hilty¹, Pascal M. Frey³, Reto A.
9 Schuepbach^{1**}, Silvio D. Brugger^{2**}

10

11

12 ¹ Institute for Intensive Care Medicine, University Hospital Zurich and University of Zurich,
13 Zurich, Switzerland

14 ² Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich,
15 University of Zurich, Zurich, Switzerland

16 ³ Department of General Internal Medicine, Bern University Hospital, University of Bern, Bern,
17 Switzerland

18 ⁴ Department of Quantitative Biomedicine, University Hospital Zurich, and University of Zurich,
19 Zurich, Switzerland

20

21 * These authors contributed equally to the work

22 ** These authors contributed equally to the work

23

24

25 Running title: Superinfection in COVID-19 patients

26

27 Correspondence to:

28 Silvio D. Brugger, M.D., Ph.D.

29 Division of Infectious Diseases and Hospital Epidemiology

30 University Hospital Zurich

31 Raemistrasse 100

32 CH-8091 Zurich

33 Switzerland

34 Phone +41 44 255 25 41 E-Mail: silvio.brugger@usz.ch

35 **Keywords:** severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coronavirus
36 disease 19 (COVID-19), acute respiratory distress syndrome (ARDS), superinfection, coinfection
37

38 **Abstract**

39

40 **Objectives**

41 While superinfections are associated with unfavourable disease course, their impact on clinical
42 outcomes in critically ill COVID-19 patients remains largely unknown. We aimed to investigate
43 the burden of superinfections in COVID-19 patients.

44

45 **Methods**

46 In this prospective single centre cohort study in an intensive care setting patients aged ≥ 18 years
47 with COVID-19 acute respiratory distress syndrome were assessed for concomitant microbial
48 infections by longitudinal analysis of tracheobronchial secretions, bronchoalveolar lavages and
49 blood. Our primary outcome was ventilator-free survival on day 28 in patients with and without
50 clinically relevant superinfection. Further outcomes included the association of superinfection
51 with ICU length of stay, incidence of bacteremia, viral reactivations, and fungal colonization.

52

53 **Results**

54 In 45 critically ill COVID-19 patients, we identified 19 patients with superinfections (42.2%) by
55 longitudinal analysis of 433 TBS, 35 BAL and 455 blood samples, respectively. On average,
56 superinfections were detected on day 10 after ICU admission. The most frequently isolated
57 clinically relevant bacteria were Enterobacteriaceae, *Streptococcus pneumoniae*, and
58 *Pseudomonas aeruginosa*.

59 Ventilator-free survival was substantially lower in patients with superinfection (subhazard ratio
60 0.37, 95%-CI 0.15-0.90, $p=0.028$). Patients with pulmonary superinfections more often had
61 bacteraemia, virus reactivations, yeast colonization, and needed ICU treatment for a significantly
62 longer time.

63

64 **Conclusions**

65 The detection of superinfections was frequent and associated with reduced ventilator-free
66 survival. Despite empirical antibiotic therapy, superinfections lead to an extended ICU stay in
67 COVID 19 patients. Longitudinal microbiological sampling in COVID-19 patients could allow
68 targeted antimicrobial therapy, and therefore minimize the use of broad-spectrum and reserve
69 antibiotics.

70

71 **Introduction**

72 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolved as the most
73 relevant pandemic of modern history, challenging health care systems all over the world. The
74 clinical characteristics of coronavirus disease (COVID-19) patients have been thoroughly
75 described in recent studies (1-5). The triggers for acute respiratory distress syndrome (ARDS) in
76 COVID-19 are initially virus-initiated, subsequently leading to inflammation-mediated lung
77 damage and endothelitis (5). Although primarily a viral disease, antibiotics are empirically used
78 in over 70% of cases in addition to experimental antiviral and immunomodulatory treatments (1,
79 4-7).

80 Secondary bacterial and/or fungal infections are a well-described phenomenon in viral illnesses
81 such as influenza and are associated with increased morbidity and mortality in viral ARDS as
82 illustrated during previous pandemics (8). Secondary bacterial infections are typically referred to
83 as superinfections whereas co-infection is mainly used to describe simultaneous virus infection.
84 Both, co- and superinfection have been described in COVID-19 patients (6, 9). Data regarding
85 bacterial superinfections in COVID-19 pneumonia are limited and still emerging (10, 11). A
86 recent systematic review has concluded that the rate of bacterial/fungal superinfections is low
87 arguing against the frequent use of broad-spectrum antimicrobials in patients with COVID-19
88 (10, 12). Still, there is a lack of knowledge about the frequency and significance of bacterial,
89 fungal and viral concomitant infections in critically ill COVID-19 patients.(12) Additionally, in
90 most studies performed so far, no thorough and systematic sampling for concomitant infections
91 was performed. The high mortality in severely ill COVID-19 patients is thought to be at least in
92 part due to secondary infections in addition to viral replication in the lower respiratory tract
93 leading to severe lung injury and ARDS (6, 13, 14).

94 Superinfection seems to represent a major risk factor for mortality in COVID-19 patients (7, 15-
95 17). However, the risk of superinfection in mechanically ventilated patients with severe COVID-
96 19 remains poorly described.

97

98 Currently, the diagnostic and treatment approach for superinfections remains unclear. Classical
99 criteria for the detection of superinfections are often of limited use in COVID-19 patients.
100 Clinical symptoms are an expression of the underlying disease of COVID-19 and cannot be used
101 to reliably distinguish between patients presenting with or without relevant superinfections. For
102 this reason, several authors have argued in favour of an empirical antibiotic treatment with a
103 focus on streptococci and staphylococci in severe courses (14). Other opinion leaders

104 recommend longitudinal sampling of severely ill patients for early detection and treatment during
105 the entire course of the disease (6, 18).

106

107 Rapid diagnosis of co- and superinfection may not only help to improve survival but would also
108 allow targeted antimicrobial therapy, improving antimicrobial stewardship throughout the course
109 of the pandemic (18, 19).

110

111 The aim of our study was to assess the burden of superinfections and the association with clinical
112 outcomes in critically ill patients with COVID ARDS (CARDS) in a tertiary care ICU with
113 highly regulated antibiotic prescription (20).

114

115

116

117 **Methods**

118

119 **Study design and population**

120 This study was performed within the MicrobiotaCOVID cohort study. The MicrobiotaCOVID
121 study is a single-centre, prospective observational study conducted at the Institute of Intensive
122 Care Medicine of the University Hospital Zurich (Zurich, Switzerland) registered at
123 clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT04410263).

124 Patients with confirmed SARS-CoV-2 infection and CARDS requiring ICU support and mainly
125 invasive mechanical ventilation hospitalized between April 2020 and June 2020 during the first
126 COVID-19 wave in Switzerland were eligible.

127 Inclusion criteria were age >18 years, SARS-CoV-2 infection as determined by real-time reverse
128 transcriptase-polymerase chain reaction (RT-PCR) positivity of nasopharyngeal and/or
129 pharyngeal swabs, TBS or BAL and hospitalization in the ICU for moderate or severe ARDS
130 according to the Berlin criteria (21).

131 Exclusion criteria were patients or relatives denying informed consent and patients still being
132 treated in the ICU when the study period ended.

133

134 **Ethics and study registration**

135 The study was approved by the local ethics committee of the Canton of Zurich, Switzerland
136 (Kantonale Ethikkommission Zurich BASEC ID 2020 - 00646).

137

138 **Study outcomes**

139 The primary outcome was ventilator-free survival on day 28. Secondary outcomes were length of
140 hospital stay, ICU stay and duration of ventilation. Further outcomes included the association of
141 pulmonary superinfection and bacteraemia, other virus co-infections, colonisation with yeast,
142 bacterial infections with multidrug resistance (MDR), and longitudinal laboratory inflammation
143 parameters.

144

145 **Sample collection, processing and testing**

146 If the respiratory situation allowed bronchoscopy, BAL was collected upon ICU admission, and
147 during the later course of the disease if medically indicated and upon discretion of the treating
148 physicians. TBS was collected from each ventilated patient at least on day 0 (i.e. upon ICU
149 admission), day 1, day 2, day 3, day 5 and henceforth every 5 days. If the clinical situation did
150 not allow TBS collection, no sampling was performed.

151 Samples were processed at the Institute for Medical Microbiology and at the Institute for
152 Medical Virology of the University of Zurich. Standard clinical microbiology techniques were
153 used for culturing, isolation and identification of bacterial and fungal microorganisms as
154 previously described (22). SARS-CoV-2 was detected by real-time RT-PCR as previously
155 described (23).

156 At admission, multiplex PCR for respiratory syncytial virus (RSV) A/B, influenza A/B,
157 adenovirus, coronavirus 229E, HKU1, NL63 and OC43, human bocavirus, human
158 metapneumovirus (hMPV), rhino/enterovirus and parainfluenzavirus 1-4 was performed in
159 nasopharyngeal swabs. Multiplex PCR for the detection of atypical respiratory bacteria was
160 performed on pharyngeal swabs at ICU admission.

161 Moreover, we assessed serum detection and virus load of the following viruses: herpesviridae
162 (herpes simplex type I and II (HSV 1 and 2), cytomegalovirus (CMV), Epstein-Barr virus (EBV)
163 and human herpes virus 6 (HHV6). Additional virus diagnostics, blood and urine cultures were
164 initiated by the treating physicians according to the clinical situation.

165

166 **Data collection and covariates**

167 Clinical and laboratory data were obtained from electronic health records and included
168 demographics, comorbidities / risk factors, medication, ICU scores, laboratory values, organ
169 failure, need for invasive ventilation, need for extracorporeal life support (ECLS), rescue
170 therapies, length of ICU/hospital stay, and experimental therapy (steroids, hydroxychloroquine,
171 lopinavir/ritonavir, remdesivir, tocilizumab and empiric antibiotic therapy).

172 Daily measurements of inflammatory parameters (CRP/PCT), the leukocyte count and the
173 neutrophil/lymphocyte ratio were routinely performed over the first 16 days after ICU admission.

174

175 **Definition of a clinically relevant microorganism in respiratory specimens (TBS and BAL)** 176 **as a proxy for superinfection**

177 The isolation of clinically relevant microorganisms from respiratory specimen cultures of
178 critically ill COVID-19 patients (TBS and/or BAL) was used as a surrogate parameter for
179 superinfection in concordance with clinical and radiological data. Patients were considered
180 positive for clinically relevant microorganisms if the following pathogens were detected in TBS
181 or BAL: *Streptococcus pneumoniae*, *Staphylococcus aureus*, *Klebsiella* spp., *Haemophilus*
182 *influenzae*, *Escherichia coli*, *Enterobacter*, *Citrobacter* spp., *Pseudomonas aeruginosa*, and
183 *Aspergillus* spp (24).

184 Consultants of the infectious disease department unrelated to the study group were involved
185 daily in the diagnosis and management of patients including specific antimicrobial treatment.
186 Organisms with low pathogenicity for lung infections such as *Enterococcus* spp., *Candida* spp.,
187 coagulase-negative Staphylococci and non-pneumococcal Streptococci were reported but not
188 considered a relevant clinical pathogen of the airways in accordance with the literature (25).
189 Detection of the herpesviridae herpes simplex 1 and 2 as well as cytomegalovirus, Epstein-Barr
190 virus, human herpes virus 6 in blood were also reported but were considered to be reactivations.
191 Viral co-infections/reactivations were only diagnosed if clinical signs of tracheitis or
192 pathological signs of viral co-infection in cytology were observed.

193

194 **Statistical analyses**

195 Due to the unknown rate of concomitant infections in severely ill COVID-19 patients a power
196 calculation was not feasible. Comparisons of population characteristics were performed using
197 Mann-Whitney-U tests and the chi-squared/Fisher exact test for categorical variables, as
198 appropriate. For longitudinal analysis of laboratory parameters, differences between time points
199 and superinfection status were tested using linear mixed effects models. To estimate the effect of
200 superinfections on 28-day ventilator-free survival, we used a competing risk regression model
201 according to Fine & Gray censored at 28 days, with the event of extubation as outcome event and
202 death as the competing risk. An alpha level of 0.05 was considered statistically significant.
203 Statistical analysis was performed using STATA version 15 (StataCorp, College Station, TX), R
204 version 3.6.3 (r-project.org/), SPSS Version 23 (SPSS Science, Chicago, IL, USA) and Graphpad
205 Prism 7 (San Diego, CA, USA).

206

207 **Results**

208 **Cohort characteristics**

209 A total of 48 critically ill COVID-19 patients with ARDS were screened in ICU at the University
210 Hospital Zurich between April and June 2020. Three patients had to be excluded from the
211 analysis because patients or relatives denied informed consent (Figure 1). 45 patients with a
212 median age of 60 (54-69) years were included in this study. Most of them were male (35/45,
213 77.8%). Of the 45 patients, 19 (42.2%) were diagnosed with a superinfection. The median of
214 ventilation duration was 15 days and length of ICU stay was 14 days overall. The median length
215 of hospital stay was 24 days. Baseline characteristics are summarised in Table 1. In general, both
216 groups of patients with and without superinfections were similar with regards to demographics
217 and clinical characteristics. In particular, there were no differences in the severity of the disease
218 and organ dysfunction as assessed by SAPS II and SOFA scores. Intensive care rescue therapies
219 such as prone position (42% vs 90%) and tracheotomy (23% vs 74%) were required more
220 frequently and/or for longer periods in the superinfection group (Table 1).

221

222 **Microbiological sampling and superinfections**

223 Overall, 433 TBS, 35 BAL samples and 455 blood culture pairs were analysed for the presence
224 of relevant microorganisms (Figure 1).

225 Clinically relevant microorganisms were detected in TBS in almost half the cases. In nineteen
226 patients (42.2%) at least one clinically relevant bacterium or fungus was detected in TBS during
227 the study period, whereas in 26 patients (57.8%) no relevant microorganisms were detected in
228 TBS.

229 A total of 319 TBS were collected in the superinfection group and 124 relevant microorganisms
230 were detected in these samples. Furthermore, relevant pathogens were detected six times in 23
231 BAL samples (26.1%). Only in two cases relevant results did not match between BAL and TBS.
232 Despite high frequency of positive TBS, blood cultures showed only seven different bacterial
233 species in twelve positive blood culture pairs (Figure 1).

234 In the group without superinfections, 83/114 TBS samples showed growth but without recovery
235 of clinically relevant lung pathogens. *Candida albicans* was the most frequently isolated non-
236 relevant organism. In BAL there was also no evidence of relevant microorganisms in the 12

237 samples. However, clinically relevant bacteraemia was detected twice in a total of 152 blood
238 culture pairs (Figure 1).

239 The detection time points of clinically relevant and non-relevant microorganisms are depicted in
240 Figure 2. On average, clinically relevant pathogens were detected on day ten after ICU admission
241 and reflect the hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia (VAP)
242 spectrum (Figure 2A). Non-relevant pathogens were detected on average on day three post ICU
243 admission (Figure 2B). The most frequently isolated bacteria per patient were detected:
244 *Enterococcus* spp. (15/45), *Enterobacter/Citrobacter* (8/45) and *Klebsiella* spp. (7/45).
245 Additionally, *Streptococcus pneumoniae* (2/45), *Escherichia coli* (2/45), *Enterobacter* spp.
246 (5/45), *Citrobacter* spp. (3/45), *Pseudomonas aeruginosa* (5/45), *Burkholderia cepacia* (2/45)
247 and Staphylococci (all coagulase-negative) (13/45)

248 Empirical antimicrobial therapy was given to 40/45 (88.9%) patients, antifungal therapy to 10/45
249 (22.2%) patients and antiviral therapy to treat concomitant viral infections to 9/45 (20 %)
250 patients. Figures 2C and D summarize the antibiotic treatment.

251 In ten patients (22.2%) multi drug resistant (MDR) bacteria were detected (*Pseudomonas*
252 *aeruginosa*, *Entereobacter cloacae* and *Burkholderia cepacia*).

253 Serum reactivation of HSV 1 and 2 was detected in 5 out of 45 patients. HHV 6 was detected
254 twice, CMV reactivation occurred once and EBV reactivation twice. One patient had a co-
255 infection with influenza A (Table 2).

256 Furthermore, colonisations with fungi were detected and the isolated organisms included
257 *Candida* spp. (29/45 patients), non-*Candida* yeast (21/45 patients) and *Aspergillus* spp. (5/45
258 patients). A detailed overview of relevant pathogens detected in TBS and blood cultures are
259 shown in Table 2.

260

261 **Ventilator-free survival at 28 days**

262 COVID-19 patients with pulmonary superinfections had a substantially lower 28-day ventilator-
263 free survival than those without superinfections (Figure 3), with a subhazard ratio of 0.37 (95%
264 Confidence Interval 0.15 – 0.90, $p = 0.028$).

265

266 **Secondary outcomes**

267 Patients with superinfections detected in respiratory specimens were ventilated for significantly
268 longer time periods (8 vs 37 days, $p<0.001$) and had a significantly longer duration of stay in the
269 ICU (9 vs 39 days, $p<0.001$) and overall hospitalization time (17 vs 44 days, $p<0.001$) as
270 compared to patients without superinfections (Table 2).

271

272 **Further outcomes**

273 Patients with pulmonary superinfections had significantly more bacteraemia ($p=0.004$), virus co-
274 infections other than SARS-CoV-2 ($p=0.001$), colonisation with yeast ($p=0.004$) and infections
275 with MDR pathogens ($p<0.001$) (Table 2).

276 Longitudinal laboratory inflammation parameters (leukocytes, CRP, PCT and
277 Neutrophil/Lymphocyte ratio) for days 1-16 are shown in Supplemental Figure 1A and
278 Supplemental Table 1. Only for CRP, the mixed model evaluation showed a significant
279 difference with increased CRP in the superinfection group ($p <0.001$). (Supplemental Figure 1 B,
280 C and D).

281

282 **Discussion**

283 In this prospective cohort study of critically ill, ventilated COVID-19 patients the presence of
284 respiratory bacteria as a proxy of superinfection was associated with extended ventilation times,
285 increased duration of intensive care and hospitalization and increased need for intensive-care
286 rescue therapies. Bacterial superinfections were detected in 42.2% of patients in our cohort,
287 which is slightly higher than reported in previous studies (1, 2, 5, 6, 13, 14, 26). This discrepancy
288 with other studies might be mainly due to the nature of our cohort consisting of severely ill
289 patients with CARDS. In addition, differing from other studies, sampling was prospectively and
290 repetitively scheduled and not only performed at admission as in other studies, which may
291 account for under-reporting of superinfections. Regional differences can also play an important
292 role especially in bacterial superinfections and spectrum of resistance. This can explain the
293 increased rate of superinfections compared to the existing meta-analyses (10, 27, 28).

294 Although some studies have concluded that bacterial superinfections do not play a major role in
295 disease severity and treatment choices, the results of the present study challenges the
296 generalizability to severely ill CARDS patients (6, 10). In our cohort, isolation of relevant
297 respiratory bacteria was associated with more severe COVID-19 disease courses with
298 significantly longer duration of invasive mechanical ventilation and prolonged ICU and hospital
299 stays. Compared to other studies investigating the role of superinfection in COVID-19, duration
300 of ICU stay and length of ventilation was high, reflecting the disease severity of patients
301 included in this study (7, 10). Additionally, data on the duration of ventilation and ICU stay are
302 often missing in other studies making comparisons difficult (4, 10, 13, 29, 30). Furthermore, due
303 to the comparatively high SOFA-Score upon admission but moderate mortality, as in our cohort,
304 long-term ICU-treatment complications such as nosocomial infections become more frequent.

305 Relevant respiratory bacteria were isolated on average on day ten after ICU admission in our
306 cohort suggesting mainly nosocomial infections. In contrast to bacterial superinfections observed
307 in influenza pneumonia, COVID-19 superinfections with Gram-positive bacteria, such as
308 Pneumococci or Staphylococci, were rare in this study (31). Similar observations were also made
309 for MERS-CoV and SARS-CoV-1 associated superinfections (32-34). In this study, mainly
310 Gram-negative pathogens such as *Pseudomonas* and Enterobacteriaceae including MDR bacteria
311 were isolated, which is in line with previous reported studies (10).

312 Based on the finding that pulmonary bacterial superinfections seem to be mostly nosocomial,
313 empirical broad-spectrum antimicrobial therapy could be stopped and only treated, if pathogenic

314 bacteria are detected (12, 30). Future prospective, randomized trials to investigate the efficacy of
315 targeted antimicrobial therapy should be conducted to define best practice regarding prevention
316 and treatment of bacterial superinfections in COVID-19. The isolation of mainly Gram-negative
317 rods including MDR led to the use of reserve antibiotics after initial empirical therapy of
318 nosocomial pneumonia (Figure 2). It is important to consider the short and long-term
319 consequences that the use of antimicrobials, especially regarding broad spectrum and reserve
320 antibiotics, may have on drug-resistance. A worrisome potential consequence of the COVID-19
321 pandemic might be the long-term spread of antimicrobial resistance (AMR) due to increased
322 exposure of patients to antimicrobial agents that may have been used inappropriately (35). In this
323 framework, employment of standardized longitudinal screening with early detection and
324 susceptibility testing before establishment of targeted antimicrobial therapy, could minimize the
325 use of broad-spectrum and reserve antibiotics, thus reducing AMR.

326 The high rate of yeast detection might be associated with the widespread use of broad-spectrum
327 empirical antimicrobial therapy (36). Invasive aspergillosis was not detected (37, 38). So far,
328 only few studies have investigated fungal superinfections in COVID-19 patients (13, 17, 39).
329 The significance of viral reactivation remains unclear (10). In our study, reactivations of HSV 1,
330 HSV 2 and HHV 6 in the serum occurred in patients with bacterial superinfections. These
331 findings support the hypothesis that superinfections associated with increased COVID-19 disease
332 severity might enhance susceptibility to viral reactivations. Further studies with higher
333 participant numbers should clarify the significance of this finding.

334 In line with previous studies, conventional clinical laboratory tests such as leukocytes, PCT and
335 neutrophil/lymphocyte ratio progressions were not associated with pulmonary superinfections
336 and therefore do not seem very useful for the detection of bacterial superinfections in COVID-19
337 patients on mechanical ventilation. This complicates the diagnosis of bacterial superinfections
338 and emphasizes the importance of longitudinal microbiological diagnostics.

339 Advantages of this study are the prospective longitudinal monitoring of respiratory materials
340 with concomitant recording of demographic data, microbiological evaluations and antimicrobial
341 therapy in a tertiary care centre in a high-resource setting that did not experience health care
342 shortage during the first pandemic wave. Furthermore, this study used strict definitions for
343 relevant respiratory pathogens and the diagnosis of superinfections was performed prospectively
344 on defined days longitudinally with detection not only of bacterial but also fungal and viral
345 super- and co-infections.

346 Limitations of the study are the single centre design, small number of patients and the high
347 number of patients with empirical broad-spectrum antibiotic therapy (>90% of cases) at
348 admission. Another limitation is the lack of a uniform internationally valid definition of a
349 bacterial infection of the lower respiratory tract.

350 In summary, the detection of relevant bacterial pulmonary superinfection was associated with a
351 more severe disease course in COVID-19 patients, especially a lower likelihood of ventilator-
352 free survival at 28 days. Future trials should investigate the effect of tailored antimicrobial
353 therapy on outcome, antibiotic resistance and drug use based on longitudinal assessment of
354 respiratory tract cultures.

355

356 **Transparency Declaration**

357 **Conflicts of interest**

358 All authors declare no conflicts of interest in this paper.

359 **Funding**

360 Promedica Foundation 1449/M to SDB and unrestricted funds to RAS. The funders had no role
361 in study design, performance, analysis and interpretation of findings.

362 **Authors' contributions**

363 PKB, ASZ, RAS, SDB designed the study and provided funding and infrastructure. PKB and
364 SDB were responsible for the ethical approval. PKB, PWG, DAH, PMF and SDB performed the
365 statistical analysis. PKB, ASZ, DAH, PDW, CTA, AGM, SMS, FA, MAM, JB, MPH, PMF,
366 RAS and SDB collected, analysed and interpreted the data. PKB, DAH, SDB, ASZ and FA
367 wrote the first draft of the manuscript.

368 All authors revised the manuscript and approved the final version.

369
370
371
372

373 **References**

- 374 1. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline
375 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the
376 Lombardy Region, Italy. *Jama*. 2020.
- 377 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with
378 2019 novel coronavirus in Wuhan, China. *Lancet* (London, England). 2020;395(10223):497-506.
- 379 3. Wendel Garcia PD, Fumeaux T, Guerci P, Heuberger DM, Montomoli J, Roche-Campo F, et al.
380 Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with
381 COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort.
382 *EClinicalMedicine*.
- 383 4. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory
384 Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.
385 *JAMA internal medicine*. 2020.
- 386 5. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with
387 Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-33.
- 388 6. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and
389 fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial
390 prescribing. *Clin Infect Dis*. 2020.
- 391 7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of
392 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* (London, England).
393 2020.
- 394 8. Martin-Loeches I, Sanchez-Corral A, Diaz E, Granada RM, Zaragoza R, Villavicencio C, et al.
395 Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1)
396 virus. *Chest*. 2011;139(3):555-62.
- 397 9. Kreitmam L, Monard C, Dauwalder O, Simon M, Argaud L. Early bacterial co-infection in ARDS
398 related to COVID-19. *Intensive care medicine*. 2020:1-3.
- 399 10. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic
400 review and meta-analysis. *The Journal of infection*. 2020.
- 401 11. Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection
402 among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting.
403 *Clinical Microbiology and Infection*. 2020.
- 404 12. Coppola S, Ciabattini A, Pozzi T, Castagna V, Bassi GL, Chiumello D. Hazardous mismatch
405 between pulmonary pathogens and antibiotic treatments in COVID-19 patients. *British journal of*
406 *anaesthesia*. 2020.
- 407 13. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill
408 patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational
409 study. *Lancet Respir Med*. 2020;8(5):475-81.
- 410 14. Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies for 2019
411 novel coronavirus disease in fever clinics. *Lancet Respir Med*. 2020;8(3):e11-e2.
- 412 15. He Y, Li W, Wang Z, Chen H, Tian L, Liu D. Nosocomial infection among patients with COVID-19:
413 A retrospective data analysis of 918 cases from a single center in Wuhan, China. *Infection control and*
414 *hospital epidemiology*. 2020;41(8):982-3.
- 415 16. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19
416 based on an analysis of data of 150 patients from Wuhan, China. *Intensive care medicine*. 2020.
- 417 17. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics
418 of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* (London,
419 England). 2020;395(10223):507-13.
- 420 18. Cox MJ, Loman N, Bogaert D, O'Grady J. Co-infections: potentially lethal and unexplored in
421 COVID-19. *The Lancet Microbe*.
- 422 19. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of Co-infection Between SARS-CoV-2 and
423 Other Respiratory Pathogens. *Jama*. 2020;323(20):2085-6.
- 424 20. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, et al. COVID-19 pneumonia:
425 different respiratory treatments for different phenotypes? *Intensive care medicine*. 2020;46(6):1099-102.
- 426 21. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute
427 respiratory distress syndrome: the Berlin Definition. *Jama*. 2012;307(23):2526-33.
- 428 22. Frey PM, Marti GR, Droz S, de Roche von Arx M, Suter-Riniker F, Aujesky D, et al. Bacterial
429 colonization of handheld devices in a tertiary care setting: a hygiene intervention study. *Antimicrobial*
430 *resistance and infection control*. 2019;8:97.

- 431 23. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel
432 coronavirus (2019-nCoV) by real-time RT-PCR. *Euro surveillance : bulletin European sur les maladies*
433 *transmissibles = European communicable disease bulletin*. 2020;25(3).
- 434 24. Patterson TF, Thompson GR, 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al.
435 *Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious*
436 *Diseases Society of America*. *Clin Infect Dis*. 2016;63(4):e1-e60.
- 437 25. Chastre J, Fagon JY. Ventilator-associated pneumonia. *American journal of respiratory and*
438 *critical care medicine*. 2002;165(7):867-903.
- 439 26. Clancy CJ, Nguyen MH. COVID-19, superinfections and antimicrobial development: What can we
440 expect? *Clin Infect Dis*. 2020.
- 441 27. Barrasa H, Rello J, Tejada S, Martín A, Balziskueta G, Vinuesa C, et al. SARS-CoV-2 in Spanish
442 Intensive Care Units: Early experience with 15-day survival in Vitoria. *Anaesthesia, critical care & pain*
443 *medicine*. 2020.
- 444 28. Tagarro A, Epalza C, Santos M, Sanz-Santaefemia FJ, Otheo E, Moraleda C, et al. Screening
445 and Severity of Coronavirus Disease 2019 (COVID-19) in Children in Madrid, Spain. *JAMA pediatrics*.
446 2020.
- 447 29. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of Co-infection Between SARS-CoV-2 and
448 Other Respiratory Pathogens. *Jama*. 2020.
- 449 30. Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infection with respiratory pathogens among
450 COVID-2019 cases. *Virus research*. 2020;285:198005.
- 451 31. Martin-Loeches I, van Someren Greve F, Schultz MJ. Bacterial pneumonia as an influenza
452 complication. *Current opinion in infectious diseases*. 2017;30(2):201-7.
- 453 32. Arabi YM, Balkhy HH, Hayden FG, Bouchama A, Luke T, Baillie JK, et al. Middle East
454 Respiratory Syndrome. *N Engl J Med*. 2017;376(6):584-94.
- 455 33. Assiri A, Al-Tawfiq JA, Al-Rabeeh AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al.
456 Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory
457 syndrome coronavirus disease from Saudi Arabia: a descriptive study. *The Lancet Infectious diseases*.
458 2013;13(9):752-61.
- 459 34. Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, Butany J. Pulmonary pathology of
460 severe acute respiratory syndrome in Toronto. *Modern pathology : an official journal of the United States*
461 *and Canadian Academy of Pathology, Inc*. 2005;18(1):1-10.
- 462 35. Rawson TM, Moore LSP, Castro-Sanchez E, Charani E, Davies F, Satta G, et al. COVID-19 and
463 the potential long-term impact on antimicrobial resistance. *The Journal of antimicrobial chemotherapy*.
464 2020.
- 465 36. de Oliveira Santos GC, Vasconcelos CC, Lopes AJO, de Sousa Cartágenes MDS, Filho A, do
466 Nascimento FRF, et al. Candida Infections and Therapeutic Strategies: Mechanisms of Action for
467 Traditional and Alternative Agents. *Front Microbiol*. 2018;9:1351.
- 468 37. Koehler P, Cornely OA, Böttiger BW, Dusse F, Eichenauer DA, Fuchs F, et al. COVID-19
469 associated pulmonary aspergillosis. *Mycoses*. 2020;63(6):528-34.
- 470 38. Wang J, Yang Q, Zhang P, Sheng J, Zhou J, Qu T. Clinical characteristics of invasive pulmonary
471 aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. *Critical care*
472 *(London, England)*. 2020;24(1):299.
- 473 39. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease
474 2019 in Wuhan, China. *Clin Infect Dis*. 2020.

475

Table 1. Demographic and clinical characteristics as well as risk factors of COVID-19 patients stratified according to presence or absence of relevant pathogens in tracheobronchial secretions (TBS) reflecting superinfection. The data are presented as median (IQR) or number and (percentage %). The two groups were compared using Chi-Square Test/Fisher Exact method for nominal distributed data or the Mann Whitney test for scale level distributed data. The significance level is $p < 0.05$.

	Overall (n=45)	No Superinfection (n=26)	Superinfection (n=19)	P-value
Baseline Characteristics				
Age median (IQR) in years	60 (54-69)	61.5 (54-71)	59 (54-69)	0.654
Male [n/%]	35 (77.8%)	19 (73.1%)	16 (84.2%)	0.375
Weight [kg]	83 (75-99)	80 (72.5-90)	92 (78-100)	0.049
Height [cm]	175 (165-182)	172 (160-180)	176 (169-185)	0.112
Body mass index [kg/m ²]	27.8 (25.7-31.6)	27.5 (25.6-30.6)	27.8 (26.8-35)	0.346
Comorbid conditions				
Myocardial Infarction / Ischemic Heart Disease	6 (13.3%)	5 (19.2%)	1 (5.3%)	0.222
Art Hypertension	26 (57.8%)	16 (61.5%)	10 (52.6%)	0.550
Chronic kidney disease	12 (26.7%)	10 (38.5%)	2 (10.5%)	0.047
Dialysis	1 (2.2%)	1 (3.8%)	0 (0%)	0.999
Oral hypoglycaemic agents controlled diabetes	5 (11.1%)	3 (11.5%)	2 (10.5%)	0.999
Insulin-dependent diabetes	14 (31.1%)	7 (26.9%)	7 (36.8%)	0.528
Asthma	1 (2.2%)	1 (3.8%)	0 (0%)	0.999
COPD	5 (11.1%)	4 (15.4%)	1 (5.3%)	0.378
Cardiovascular disease	7 (15.6%)	6 (23.1%)	1 (5.3%)	0.211
Renal or liver transplantation	5 (11.1%)	4 (15.4%)	1 (5.3%)	0.378
Immunosuppression	7 (15.6%)	5 (19.2%)	2 (10.5%)	0.222
Tumour disease	4 (8.9%)	2 (7.7%)	2 (10.5%)	0.999
Smoking	14 (31.1%)	7 (26.9%)	7 (36.8%)	0.625
Alcohol abuse	1 (2.2%)	0 (0%)	1 (5.3%)	0.999
Drug abuse	0 (0%)	0 (0%)	0 (0%)	1.000

Medical therapy before admission				
Statins	10 (22.7%)	6 (24%)	4 (21.1%)	0.999
ACE-Inhibitor	7 (15.9%)	4 (16%)	3 (15.8%)	0.999

Scores/Index				
Sepsis-related organ failure assessment score (SOFA)	8 (5-10)	8 (3-10)	9 (7-10)	0.480
Simplified Acute Physiology Score (SAPS) II	36 (25-50)	32.5 (24-50)	42 (28-51)	0.275
PaO ₂ /FiO ₂ ratio low at admission	122 (94-177)	129 (97-200)	108 (85-163.5)	0.228

Organ failure during ICU stay				
Acute kidney disease	27 (60%)	15 (57.7%)	12 (63.2%)	0.712
Dialysis	18 (40%)	9 (34.6%)	9 (47.4%)	0.388
Ventilation Therapy	40 (88.9%)	21 (80.8%)	19 (100%)	0.043
Extracorporeal Life Support (ECLS)	8 (17.8%)	3 (11.5%)	5 (26.3%)	0.253

Rescue therapies				
Prone Position	28 (62.2%)	11 (42.3%)	17 (89.5%)	0.001
iNO	11 (24.4%)	5 (19.2%)	6 (31.6%)	0.341
Tracheotomy	20 (44.4%)	6 (23.1%)	14 (73.7%)	0.001

Timing [days]				
Time to ICU admission	2 (1-6)	2 (1-6)	3 (1-6)	0.636
Duration prone position	6 (1-10)	1.5 (1-7)	6 (4-10)	0.022
Duration iNO therapy	3 (1-6)	1 (1-3)	4.5 (1-22)	0.349
Duration Intubation to tracheotomy	20 (10-33)	10.5 (9-21)	27 (15-33)	0.114

Laboratory values at admission				
WBC count (G/L)	7.7 (5.7-10.7)	7.5 (5.7-10)	8 (5.3-13.4)	0.515
Haemoglobin (gr/l)	118.5 (101.5-133)	117 (107-132)	126 (98-134)	0.896
Haematocrit (%)	0.4 (0.3-0.4)	0.4 (0.3-0.4)	0.4 (0.3-0.4)	0.619
Platelet count (G/L)	199 (169.5-272)	200 (177-271)	190 (154-297)	0.776
ALT(U/L)	42.5 (25.5-65.5)	31 (24-60)	56 (33-72)	0.008
LDH (U/L)	676 (527-842.5)	619 (471-742)	772 (626-876)	0.144
Alkaline Phosphatase (U/L)	74.5 (53.5-103.5)	77.5 (56-108)	61 (53-98)	0.308

Urea (mmol/l)	6 (4.3-10.3)	6.2 (4.1-7.9)	6 (4.4-12.2)	0.651
Creatinine (umol/l)	92.5 (67-138.5)	95 (70-128)	91 (57-149)	0.387
Serum Sodium (mmol/L)	138 (134-141)	137 (135-140)	141 (134-146)	0.203
Serum potassium (mmol/L)	3.9 (3.7-4.5)	4.1 (3.7-4.4)	3.8 (3.5-4.7)	0.601
CRP (mg/L)	168.5 (83.5-276.5)	124 (62-238)	255 (102-301)	0.034
PCT (mcg/L)	0.3 (0.2-1.2)	0.2 (0.1-1.7)	0.4 (0.2-1.2)	0.060
IL6 (ng/L)	127 (71.2-454)	122 (84-697)	127 (62.7-263)	0.554

Special drug therapy				
Steroids	21 (46.7%)	8 (30.8%)	13 (68.4%)	0.012
Hydroxychloroquine	27 (61.4%)	13 (52%)	14 (73.7%)	0.143
Lopinavir/ritonavir	7 (15.9%)	4 (16%)	3 (15.8%)	0.999
Remdesivir	8 (18.2%)	4 (16%)	4 (21.1%)	0.704
Tocilizumab	2 (4.7%)	2 (8.3%)	0 (0%)	0.501
empiric antimicrobial therapy	40 (88.3%)	22 (88%)	18 (94.7%)	0.441

Sample size overall				
TBS	433	114	319	
BAL	35	12	23	
Blood culture	455	152	303	


Table 2 Clinical outcomes and microorganisms detected


The data are presented as median (95 CI of Median) or number and (percentage %). 95%CI of the difference or Relative Risk (95 CI) were calculated too. The two groups were compared using Chi-Square Test/Fisher Exact method for nominal distributed data or the Mann Whitney test for scale level distributed data. The significance level is $p < 0.05$.


	No Superinfection (n=26)	Superinfection (n=19)	95%CI of the difference or Relative Risk (95 CI)	p-value
Timing				
Duration ventilation	8 (5.9 - 15.1)	37 (22.2 - 43.7)	10 to 34	<0.001
Duration ICU	9 (7.0 - 14.9)	39 (28.5 - 57.0)	15 to 38	<0.001
Duration hospitalisation	17 (14.4 - 26.4)	44 (34.2 - 63.3)	10 to 41	<0.001
Superinfection data				
Patients died	6 (23.1%)	4 (21.1%)	0.95 (0.58 to 1.92)	0.999
Patients with bacterial respiratory superinfection	0 (0%)	19 (100%)		
Patients with superinfection in BAL	0 (0%)	6 (31.6%)	infinity (1.674 to infinity)	0.003
Patients with bloodstream infection	2 (7.7%)	9 (47.4%)	10.8 (1.92 to 53.53)	0.004
Patients with virus infection	1 (3.85%)	9 (47.4%)	7.143 (1.72 to 40.27)	0.001
Patients with aspergillus detection	2 (7.7%)	3 (15.8%)	1.5 (0.72 to 5.20)	0.636
Patients with Yeast detection	12 (46.2%)	17 (89.5%)	2.17 (1.33 to 3.51)	0.004
Patients with multi drug resistant pathogens	0 (0%)	10 (52.6%)	infinity (6.076 to infinity)	<0.001
Causative microbiology				
Microbiology of TBS superinfections				
Overall pathogen detection in TBS	83	368		
Relevant pathogen detection in TBS	0 (0%)	124 (33.7%)		
<i>Citrobacter freundii, koseri</i>	0 (0%)	8 (2.2%)		
<i>Enterobacter cloacae</i>	0 (0%)	9 (2.5%)		
<i>Escherichia coli</i>	0 (0%)	2 (0.5%)		
<i>Klebsiella aerogenes</i>	0 (0%)	8 (2.2%)		
<i>Klebsiella pneumoniae</i>	0 (0%)	18 (4.8%)		
<i>Legionella pneumophila</i>	0 (0%)	2 (0.5%)		
<i>Pseudomonas aeruginosa</i>	0 (0%)	49 (13.3%)		

<i>Streptococcus pneumoniae</i>	0 (0%)	2 (0.5%)
<i>Burkholderia cepacia</i>	0 (0%)	24 (6.5%)
<i>Morganella morganii</i>	0 (0%)	2 (0.5%)
Microbiology of bloodstream superinfections		
Overall relevant positive detection	2/152 (1.3%)	12/303 (4.0%)
<i>Citrobacter</i>	0 (0%)	2 (16.7%)
<i>Enterococci faecalis and faecium</i>	1 (50%)	6 (50%)
<i>Klebsiella aerogenes</i>	0 (0%)	1 (8.3%)
<i>Klebsiella pneumonia</i>	0 (0%)	1 (8.3%)
<i>Moraxella spp</i>	1 (50%)	0 (0%)
<i>Candida glabrata</i>	0 (0%)	1 (8.3%)
<i>Pseudomonas aeruginosa</i>	0 (0%)	1 (8.3%)
PCR diagnostic		
Atypical pneumonia pathogens (n=35)	0 (0%)	1 (%) (Legionella)
Causative virology superinfection		
Overall	2	9
Influenza A	0 (0%)	1 (11.1%)
Influenza B	0 (0%)	0 (0%)
Respiratory viruses block analysis (n=34)	0 (0%)	0 (0%)
HSV 1 (PCR in blood)	0 (0%)	5 (55.5%)
HSV 2 (PCR in blood)	0 (0%)	0 (0%)
HHV6 (PCR in blood)	0 (0%)	2 (22.2%)
CMV (PCR in blood)	1 (50%)	0 (0%)
EBV (PCR in blood)	1 (50%)	1 (11.1%)


Figure 1. Study Flow Diagram









excludes outside values



excludes outside values



Proportion of ventilator-free survivors within 28 days



Number at risk						
Superinfection	19		16	16	12	11
No superinfection	21		13	5	3	1

